Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

ORION B

ORNBV.HEFI0009014377NASDAQ HelsinkiFIEUR
Stock price
ORION B
Loading chart...

Coverage

Latest articles

U.S. FDA approves new indication for Orion-Bayer prostate cancer drug
8 Jun 2025, 20:27ORNBV.HENASDAQ Helsinki

Filings

Recent filings

FilingDate
SHARE ACQUISITIONS 16/08/201016 Aug 2010
SHARE ACQUISITIONS 13/08/201013 Aug 2010
435,019 Orion A-shares converted into B-shares13 Aug 2010
SHARE ACQUISITIONS 12/08/201012 Aug 2010
SHARE ACQUISITIONS 11/08/201011 Aug 2010
CORRECTION: SHARE ACQUISITIONS 11/08/201011 Aug 2010
Orion Group Interim Report January-June 201010 Aug 2010
Orion Corporation's publication schedules for financial reporting in 2011
Search

Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).

  • Previous
  • 1
  • 2
  • Next
10 Aug 2010
Orion invites analysts and media to Q2 news conference on Tuesday 10 August 201019 Jul 2010
Orion and Sun settle patent dispute22 Jun 2010
20,138 Orion A-shares converted into B-shares17 Jun 2010
Composition of R&D Committee as of 15 June 201015 Jun 2010
  • Previous
  • 1
  • More pages
  • 68
  • 69
  • 70
  • More pages
  • 95
  • Next
Company
ORION B
ORNBV.HENASDAQ Helsinki
Website: Unavailable
Coverage
7
Filings
1,130